An ascending single and multiple dose study of the safety, tolerability, pharmacokinetics, and pharmacodynamics of HKI-272 [neratinib] administered orally to subjects with HER-2/NEU or HER-1/EGFR [epidermal growth factor receptor]-positive tumors

Trial Profile

An ascending single and multiple dose study of the safety, tolerability, pharmacokinetics, and pharmacodynamics of HKI-272 [neratinib] administered orally to subjects with HER-2/NEU or HER-1/EGFR [epidermal growth factor receptor]-positive tumors

Completed
Phase of Trial: Phase I

Latest Information Update: 11 May 2012

At a glance

  • Drugs Neratinib (Primary)
  • Indications Tumours
  • Focus Adverse reactions
  • Most Recent Events

    • 11 May 2012 Additional company (Puma Biotechnology) added in association as reported by ClinicalTrials.gov.
    • 11 May 2012 Actual patient number is 72 according to ClinicalTrials.gov.
    • 04 Dec 2007 Status changed from in progress to completed as reported on clinicaltrials.gov website.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top